The cytoprotective drug rebamipide in therapy for inflammatory and erosive-ulcerative lesions of the gastrointestinal tract


Cite item

Full Text

Abstract

Rebamipide is a cytoprotесtive drug that stimulates the generation of endogenous prostaglandins in the gastric and small intestinal mucosa and accelerates the healing of erosions and ulcers caused by Helicobacter pylori infection and NSAID administration. The major properties of rebamipide include stimulation of prostaglandins and synthesis of muсus glycoproteins, inhibition of reactive oxygen species, inflammatory cytokines, and chemokines, and suppression of neutrophil activation. This paper shows the ability of rebamipide to enhance the efficiency of therapy for Helicobacter pylori-induced infection, to reduce inflammation, including that after infection eradication, to accelerate ulcer healing, and to prevent the progression of preneoplastic lesions.

References

  1. Rose S, ed. Gastrointestinal and Hepatobiliary pathophysiology. Madison, Connecticut: Fence Greek Publishing, LLC; 1998.
  2. Whittle BJR. Protective mechanisms of the gastric mucosa. In Gustavsson S, Kumar D, Graham DY, eds. The stomach. Edinburgh, London, Madrid: Churchill Livingstone; 1992:81-101.
  3. Sol AH. Peptic ulcer and its complications. In Sleisenger M, Fordtrans JS, eds. Gastrointestinal and Liver Disease. Philadelphia-London-Toronto-Monreal-Sydney-Tokyo; 2003.
  4. Григорьев П.Я., Яковенко А.В. Клиническая гастроэнтерология. 3-е издание. М.: МИА; 2004.
  5. Feldman M, Scharschmidt BF, Sleisenger MH, Fordtran JS, eds. Sleisenger and Fordtran‘s Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 6th ed. W.B. Saunders Company; 1998.
  6. Яковенко Э.П., Яковенко А.В., Илларионова Ю.В., Иванов А.Н., Агафонова Н.А., Прянишникова А.С., Солуянова И.П. Ингибиторы протонной помпы в профилактике и терапии стрессовых язв. Лечащий врач. 2010;(2):52-55.
  7. Яковенко Э.П., Яковенко А.В., Илларионова Ю.В., Агафонова Н.А., Лаврентьева С.А, Иванов А.Н., Прянишникова А.С., Краснолобова Л.П. Пантопразол в терапии кислотозависимых заболеваний. Фарматека. 2012;2:45-50.
  8. Кононов А.В. Гетерогенность воспалительного ответа в популяции при Helicobacter pylori-инфекции. Педиатрия. 2002;2(прил.):124-130.
  9. Prichard P, Walt R, Chapman R. Drugs for the GUT. A practical guide to gastrointestinal and liver therapy. London, Philadelphia, Toronto, Sydney: WB Saunders company limited; 1998.
  10. Яковенко А.В., Григорьев П.Я., Яковенко Э.П., Агафонова Н.А., Прянишникова А.С., Иванов А.Н., Алдиярова М.А., Солуянова И.П., Анашкин В.А., Оприщенко И.В. Цитопротекторы в терапии заболеваний желудка. Оптимальный подход к выбору препарата. Клиническая и экспериментальная диагностика. 2006;2:56-60.
  11. Arakawa T, Higuchi K, Fujiwara Y et al. 15th Anniversary of Rebamipide: Looking Ahead to the New Mechanisms and New Applications. Dig Dis Sci. 2005;50(1):S3-S11. doi: 10.1007/s10620-005-2800-9.
  12. Nebiki H, Higuchi K, Arakawa T et al. Effect of rebamipide on Helicobacter pylori infection in patients with peptic ulcer. Dig Dis Sci. 1998;(43):203-206.
  13. Haruma K, Ito М, Kido S et al. Long-term rebamipide therapy improves Helicobacter pylori-associated chronic gastritis. Dig Dis Sci. 2002;47:862-867. doi: 10.1023/a:1014716822702.
  14. Higuchi K, Arakawa T, Nebiki H et al. Rebamipide prevents recurrence of gastric ulcers without affecting Helicobacter pylori status. Dig Dis Sci. 1998;43:99S-106S.
  15. Kim H, Seo JY, Kim KH. Inhibition of lipid peroxidation, NFkappaB activation and IL-8 production bу rebamipide in Helicobacter pylori-stimulated gastric epithelial cells. Dig Dis Sci. 2000;45:621-628. doi: 10.1023/a:1005474013988.
  16. Takaishi O, Arakawa T, Yamasaki K, Fujiwara Y, Uchida T, Tominaga K, Watanabe T, Higuchi K, Fukuda T, Kobayashi K and Kuroki T. Protective effect of rebamipide against ammonia-induced gastric mucosal lesions. Dig Dis Sci. 1998;43:78s-82s.
  17. Мatysiak-Budnik T, Thomas-Collignon A, Megraud F, Heyman M. Alterations of epithelial permeability by HeIicobacter and IL-Iβ in vitro: protective effect of rebamipide. Dig Dis Sсi. 2001;46:1558-1566. doi: 10.1023/a:1010664626431.
  18. Nebiki H, Atakawa T, Higuchi K, Kobayashi K. Quality of ulcer healing influences the relapse of gastic ulcers in humans. J Gastroentrol Hepatol. 1997;12:109-114. doi: 10.1111/j.1440-1746.1997.tb00393.x.
  19. Takayama M. Efficacy of treatment with rebamipide for endoscopic submucosal dissection-induced ulcers. World J Gastroenterol. 2013;19(34):5706-5712. doi: 10.3748/wjg.v19.i34.5706.
  20. Ishihara K, Komuro Y, Nishiyama N et al. Effect of rebamipide on mucus secretion by endogenous prostaglandin-independet mechanism. Drag Res. 1992;42:1462-1466.
  21. Watanabe S, Wang X-E, Hirose M. et al. Effects of rebamipide on bile acid induced inhibition of gastric epithelial repair in a rabbit cell culture model. Aliment Pharmacol Ther. 1996;10(6):927-932. doi: 10.1046/j.1365-2036.1996.105276000.x.
  22. Tarnawski A, Arakawa T, Kobayashi K. Rebamipide treatment activates EGF and its receptor expression in normal and ulcerated gastric mucosa. The molecular mechanism of its ulcer healing action. J Gastroenterol Hepatol. 1997;12(suppl):A221.
  23. Naito Y, Yoshikawa T, Iinuma S et al. Local gastric and serum concentrations of rebamipide following oral administration to patients with chronic gastritis. Arzneimittelforschung. 1996;46:698-700.
  24. Tarnawski A, Pai R, Chiou S, Chai J, Chu E. Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Commun. 2005;334(1):207-212. doi: 10.1016/j.bbrc.2005.05.204.
  25. Hawkey C. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors. Gut. 2003;52(4):600-608. doi: 10.1136/gut.52.4.600.
  26. Endo H, Sakai E, Higurashi T et al. Differences in the severity of small bowel mucosal injury based on the type of aspirin as evaluated by capsule endoscopy. Dig Liver Dis. 2012;44(10):833-838. doi: 10.1016/j.dld.2012.05.016.
  27. Takeuchi K, Tanaka A, Kato S, Amagase K, Satoh H. Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin Chim Acta. 2010;411(7-8):459-466. doi: 10.1016/j.cca.2009.12.026.
  28. Mizoguchi H, Ogawa Y, Kanatsu K, Tanaka A, Kato S, Takeuchi K. Protective effect of rebamipide on indomethacin-induced intestinal damage in rats. J Gastroenterol Hepatol. 2001;16(10):1112-1119. doi: 10.1046/j.1440-1746.2001.02592.x.
  29. Kurokawa S, Katsuki S, Fujita T et al. A randomized, double-blinded, placebo-controlled, multicenter trial, healing effect of rebamipide in patients with low-dose aspirin and/or non-steroidal anti-inflammatory drug induced small bowel injury. J Gastroenterol. 2013;49(2):239-244. doi: 10.1007/s00535-013-0805-2.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies